Literature DB >> 30652403

Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis.

Tim Friede1, Harald Pohlmann2, Heinz Schmidli3.   

Abstract

Entities:  

Keywords:  adaptive design; internal pilot study; multiple sclerosis; parametric models; sample size

Mesh：

Year:  2019        PMID： 30652403     DOI： 10.1002/pst.1927

Source DB:  PubMed          Journal:  Pharm Stat        ISSN： 1539-1604            Impact factor:   1.894


× No keyword cloud information.
  3 in total

1.  Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1).

Authors:  Nicole Krause; Karin Riemann-Lorenz; Tanja Steffen; Anne Christin Rahn; Jana Pöttgen; Jan-Patrick Stellmann; Sascha Köpke; Tim Friede; Andrea Icks; Markus Vomhof; Herbert Temmes; Markus van de Loo; Stefan M Gold; Christoph Heesen
Journal:  BMJ Open       Date:  2021-02-16       Impact factor: 2.692

2.  Design aspects of COVID-19 treatment trials: Improving probability and time of favorable events.

Authors:  Jan Beyersmann; Tim Friede; Claudia Schmoor
Journal:  Biom J       Date:  2021-10-22       Impact factor: 1.715

Review 3.  Blinding in Clinical Trials: Seeing the Big Picture.

Authors:  Thomas F Monaghan; Christina W Agudelo; Syed N Rahman; Alan J Wein; Jason M Lazar; Karel Everaert; Roger R Dmochowski
Journal:  Medicina (Kaunas)       Date:  2021-06-24       Impact factor: 2.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.